Press Room


    Press Release - June 11, 2002

    Pheromone Sciences' Successfully Completes Dairy Cow Monitoring Study

    Pheromone Sciences Corp (CDNX: PHS), today announced that it has completed the preliminary feasibility trial of its large animal fertility and ovulation detection technology for large animal breeding at the Ontario Veterinary College under the direction of Dr. Walter H. Johnson DVM, MVSc, Dipl. ACT, Professor of Theriogenology at the University of Guelph.

    The study was successful in detecting hormone- related changes indicative of heat in the majority of the dairy cows tested confirming the Company's ability to adapt its proprietary PSC Fertility Monitor technology to the specific physiology and living environment of the dairy cow. In doing so the Company intends to pursue further development of this product to predict impending estrus.

    "We are very pleased that after many months of working together with the scientific staff of Pheromone Sciences, we are able to move this project to the next stage of development toward creating a new technology that will be of significant benefit to dairy farmers at large", commented Dr. Johnson, he continued, "A product that can increase conception rates in dairy herd breeding would positively impact productivity on dairy farms across North America".

    Dairy industry researchers estimate that within the North American dairy industry U.S. producers incur revenue losses directly attributable to inefficient herd reproduction management of approx. US$400 million per annum. The ability to provide accurate monitoring of the fertility status of commercial livestock would afford a significant commercial opportunity for both the agricultural community and Pheromone Sciences Corp.

    "Results using our new sensor configuration have us quite excited," said Doug Marett, Pheromone Sciences Chief Scientific Officer. "We will now look to optimize the best location and mounting method for the device building sufficient data to generate algorithms to predict impending heat for the dairy cow."

    Christopher Neuman, President and CEO of Pheromone Sciences Corp. said, "We are very excited about the progress we have made in extending our sensor and reporting technology into a new application with such huge commercial applications."

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

    INVESTOR CONTACT Lorne Woods 1-(800) 937-3095


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News